Rahul A. Sheth, an expert in interventional oncology, Yana Najjar, a leading medical oncologist, and Douglas Johnson, a melanoma research director, dive into cutting-edge melanoma treatments. They discuss the role of oncolytic viruses in overcoming immune checkpoint resistance and share insights from the IGNITE trial. The importance of interdisciplinary collaboration between medical oncologists and interventional radiologists in administering these therapies is highlighted. They also touch on safety, workflow challenges, and the promise of innovative combination therapies for advanced cases.
